Latest Ionis News & Updates
See the latest news and media coverage for Ionis. We track all announcements, press releases, and industry mentions in real time, all in one place.
RNA- and DNA-targeted medicines developer
ionis.com- Headquarters
- Carlsbad, United States
- Founded year
- 1989
- Company type
- Public company
- Number of employees
- 500–1,600
Latest news about Ionis
Company announcements
-
Ionis presents AxD study data at AAN Meeting
They gathered in Chicago, shared positive pivotal data on Alexander Disease treatment, and discussed neurology programs with providers and advocates.
-
Ionis reports Q1 2026 financial results
Revenue rises 87% to $246M. TRYNGOLZA sales hit $27M. Olezarsen sNDA accepted for priority review. Guidance improved.
-
GSK announces FDA Priority Review for bepirovirsen
FDA grants Breakthrough Therapy Designation for the Ionis-partnered drug targeting chronic hepatitis B. PDUFA date is October 26, 2026.
-
Ionis publishes 2025 Corporate Responsibility Report
It highlights milestones in RNA medicines, pipeline progress, employee empowerment, community support, and sustainability efforts including Climate Risk Assessment.
Media coverage
-
Earnings Beat: Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) just released its first-quarter report and things are looking bullish. Revenue crushed expectations at US$246m, beating expectations by 2...
-
Narrow-Moat Ionis' Peak Sales Raised for Olezarsen; Positive Outlook as Late-Stage Assets Advance
Ionis Pharmaceuticals is a leader in RNA-based therapies. Its spinal muscular atrophy drug Spinraza, marketed by partner Biogen, is the first RNA-based therapy to achieve...
-
Ionis upgraded at JP Morgan on expanding Tryngolza market, pipeline
JP Morgan upgraded Ionis Pharmaceuticals (NASDAQ:IONS) to overweight from neutral citing a potential label expansion for Tryngolza (olezarsen) and promising candidates in its pipeline. The...
-
IONS Q1 Earnings & Sales Beat, Stock Rises on Raised '26 View
Ionis Pharmaceuticals IONS reported first-quarter 2026 adjusted loss per share of 30 cents, narrower than the Zacks Consensus ...
Track Ionis and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Ionis competitors & trending companies
Browse news for competitors to Ionis and other trending companies.
Orna Therapeutics
Wave Life Sciences
Sironax
Aperture Therapeutics
Attentive
Klaviyo
Twilio
Insider One
Zeta Global
Iterable
Braze
Optimove
Bluecore
BlueConic
Amperity
Wero
BLIK
EPI
Swish
Affirm
Brite Payments
TCS
Overview Energy
Adfin
Ineffable Intelligence
Mechanize
Hexatronic
Alimak Group
Lindab Group
NYAB
Noon Energy
Nordan AI
Mips
Vexlum